# Clearmind Medicine Inc.

Type: Company (CMND)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/clearmind-medicine-inc
Canonical HTML page: https://getbiobrief.com/entity/clearmind-medicine-inc

## Recent coverage (1 stories)

### CMND-100: Clearmind's Non-Hallucinogenic Neuroplastogen Targets 5-HT1A for AUD
2026-07-11 00:45:15 · Sentiment: Neutral · Impact: 6/10 · Sources: 4

Clearmind Medicine submitted a response to an HHS RFI highlighting its clinical-stage candidate CMND-100, an MEAI-based neuroplastogen for Alcohol Use Disorder. The drug engages 5-HT1A pathways without hallucinogenic effects, offering a novel mechanism for addiction treatment.
Full story: https://getbiobrief.com/story/clearmind-cmnd100-neuroplastogen-rfi

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.